Bolt’s first-in-class clinical candidate, BDC-1001, is a novel HER2-targeting, TLR 7/8 immune-stimulating antibody conjugate (ISAC)…
KT-413-mediated degradation of IRAK4 and IMiD substrates has synergistic effect on MYD88-NFkB and IRF4-Type 1…
VANCOUVER, BC / ACCESSWIRE / April 10, 2021 / ELSE NUTRITION HOLDINGS INC. (TSXV:BABY)(OTCQX:BABYF)(FSE:0YL) (“Else”…
Additional, ongoing confirmed durable partial response and three additional patients with stable disease as best…
WEMBLEY, ENGLAND / ACCESSWIRE / April 10, 2021 / The young business talent has been…
Data support potential of DARPin® CD3 T-cell engager candidate for improved safety window while limiting…
SHENZHEN, CHINA, Apr 11, 2021 – (ACN Newswire) – On April 8th, BYD ushered in…
CHARLOTTE, NC / ACCESSWIRE / April 10, 2021 / For some retirement investors, simply thinking…
SHERMAN OAKS, CA / ACCESSWIRE / April 9, 2021 / Petroteq Energy Inc. (“Petroteq” or…
Saint-Herblain (France), April 10, 2021 – Valneva SE (“Valneva” or the “Company”), a specialty vaccine…